AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4091992 — intervention group
Group type: EXPERIMENTAL
Intervention: retard capsule
Number of subjects: 12
Study 31548894 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin for 3 days
Number of subjects: 1126
Study 31548894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1126
Study 29428315 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone (T) and high antimüllerian hormone (AMH)
Number of subjects: 1198
Study 29428315 — intervention group
Group type: COMPARATOR
Intervention: Norm testosterone (T) and norm antimüllerian hormone (AMH)
Number of subjects: 1198
Study 27609813 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (ICBT)
Number of subjects: 945
Study 27609813 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 945
Study 27609813 — intervention group
Group type: COMPARATOR
Intervention: Usual care by a physician
Number of subjects: 945
Study 24346596 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB plus PCV7
Number of subjects: 0
Study 24346596 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐IPV‐Hib‐HepB with PCV7 administered 1 month later
Number of subjects: 0
Study 24346596 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent DTaP5‐IPV/Hib plus HepB plus PCV7
Number of subjects: 0
Study 23390790 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable toe splint for 2 weeks
Number of subjects: 36
Study 23390790 — intervention group
Group type: COMPARATOR
Intervention: Control group (proper shoes only)
Number of subjects: 36
Study 20733439 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine tablets - placebo cream
Number of subjects: 133
Study 20733439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream - placebo tablet
Number of subjects: 133
Study 20733439 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets - placebo cream
Number of subjects: 133
Study 20733439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine cream - desipramine tablet
Number of subjects: 133
Study 20733439 — intervention group
Group type: COMPARATOR
Intervention: Desipramine tablets
Number of subjects: 133
Study 20733439 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine cream
Number of subjects: 133
Study 18575435 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior decompression approach using cervical retractor systems (Group B)
Number of subjects: 92
Study 18575435 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical approach (Group A)
Number of subjects: 92
Study 15902988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water condition (20 degrees)
Number of subjects: 11
Study 15902988 — intervention group
Group type: COMPARATOR
Intervention: Neutral water condition (33 degrees)
Number of subjects: 11
Study 15902988 — intervention group
Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 11
Study 12905545 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultant-led group
Number of subjects: 1131
Study 12905545 — intervention group
Group type: COMPARATOR
Intervention: Open access group
Number of subjects: 1131
Study 10076944 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior knee pain syndrome patients (12 knees)
Number of subjects: 10
Study 10076944 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (20 knees)
Number of subjects: 10
Study 7585852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide 220 micrograms plus placebo capsule
Number of subjects: 298
Study 7585852 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine 10 mg plus placebo nasal spray
Number of subjects: 298
Study 7585852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide
Number of subjects: 298
Study 7585852 — intervention group
Group type: COMPARATOR
Intervention: Oral loratadine
Number of subjects: 298
Study 2258355 — intervention group
Group type: EXPERIMENTAL
Intervention: pefloxacin 400 mg iv
Number of subjects: 162
Study 2258355 — intervention group
Group type: COMPARATOR
Intervention: cefazolin 1.0 g iv
Number of subjects: 162
Study 7000172 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (Timoptol)
Number of subjects: 24
Study 7000172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30982092 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program (exercise, behaviour change, symptom management)
Number of subjects: 92
Study 30982092 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 30877937 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer-coated biolimus-eluting stent (BP-BES)
Number of subjects: 4255
Study 30877937 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer-coated drug-eluting stents (DP-DES)
Number of subjects: 4255
Study 27776936 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-guided PEEP
Number of subjects: 70
Study 27776936 — intervention group
Group type: COMPARATOR
Intervention: FiO2-guided PEEP
Number of subjects: 70
Study 26314702 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.03 mg/kg of the participant's body mass, to a maximum of 2.5 mg)
Number of subjects: 14
Study 26314702 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study 23442944 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance clopidogrel
Number of subjects: 6327
Study 21196617 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25‐50 mg/day
Number of subjects: 41
Study 21196617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 19480864 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified acupuncture therapy with needle insertion into multiple loci to elicit local twitch responses at acupuncture points Wai‐guan and Qu‐chi.
Number of subjects: 20
Study 19480864 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture.
Number of subjects: 20
Study 16979835 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesorectal excision (TME) and intraoperative electron‐beam radiation therapy (IOERT) with preoperative or postoperative chemoradiation (CRT)
Number of subjects: 210
Study 15283927 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg per day tibolone (OD, n = 18)
Number of subjects: 58
Study 15283927 — intervention group
Group type: EXPERIMENTAL
Intervention: daily combined 0.625 mg of conjugated estrogens 2.5 mg-1 of medroxy progesterone acetate pill (EP, n = 20)
Number of subjects: 58
Study 15283927 — intervention group
Group type: COMPARATOR
Intervention: Vitamin pill (C, n= 20)
Number of subjects: 58
Study 11275387 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (12-week trial)
Number of subjects: 78
Study 11275387 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electromyographic biofeedback (12-week trial)
Number of subjects: 78
Study 11275387 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibulectomy
Number of subjects: 78
Study 11275387 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 78
Study 9606845 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 8024627 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet formulation of sotalol hydrochloride (80 mg)
Number of subjects: 16
Study 8024627 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation of sotalol hydrochloride
Number of subjects: 16
Study 2689911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 2
Study 2689911 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine-pancuronium
Number of subjects: 2
Study 949645 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexon sutures
Number of subjects: 87
Study 949645 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures
Number of subjects: 87
Study 31451942 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioQuiz mobile app
Number of subjects: 489
Study 28588165 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (10 mg intra coronary single bolus dose)
Number of subjects: 146
Study 28588165 — intervention group
Group type: COMPARATOR
Intervention: Control (no eptifibatide)
Number of subjects: 146
Study 25921451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa 2.5 mg/d via eRapid nebulizer
Number of subjects: 87
Study 23406890 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens program (8 weekly 1-hour sessions)
Number of subjects: 535
Study 23406890 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Parents, Healthy Teens program
Number of subjects: 535
Study 21965486 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider activation through electronic dental records (EDRs)
Number of subjects: 102
Study 21965486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation through personal health records
Number of subjects: 102
Study 19589146 — intervention group
Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg with mosapride 5 mg
Number of subjects: 10
Study 20084717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine-based hepatic arterial infusion (HAI) chemotherapy
Number of subjects: 0
Study 20084717 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 14995946 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl infusion (4 ml kg‐1 over 10 min)
Number of subjects: 20
Study 14995946 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl infusion (control)
Number of subjects: 20
Study 11709597 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided learning (CAL) programme
Number of subjects: 85
Study 11709597 — intervention group
Group type: COMPARATOR
Intervention: Lecture and seminar on IOTN
Number of subjects: 85
Study 10084352 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious‐sociocultural psychotherapy
Number of subjects: 203
Study 10084352 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 203
Study 7997323 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir (400 mg 5 times daily, n = 51)
Number of subjects: 104
Study 7997323 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 53)
Number of subjects: 104
Study 7997323 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir (400 mg 5 times daily)
Number of subjects: 104
Study 7997323 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study 3180119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 0
Study 29458932 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenicum album 30cH (6 doses, thrice daily for two days)
Number of subjects: 120
Study 29458932 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable from verum)
Number of subjects: 120
Study 28104514 — intervention group
Group type: EXPERIMENTAL
Intervention: RGI-2001
Number of subjects: 29
Study 28104514 — intervention group
Group type: COMPARATOR
Intervention: Control (nonresponders)
Number of subjects: 29
Study 28104514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 29
Study 25799130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy (PJ)
Number of subjects: 98
Study 25799130 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticogastrostomy (PG)
Number of subjects: 98
Study 23035721 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 322
Study 23035721 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 322
Study 23035721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 20375503 — intervention group
Group type: EXPERIMENTAL
Intervention: Spine surgery under general anesthesia
Number of subjects: 10
Study 20375503 — intervention group
Group type: COMPARATOR
Intervention: Spine surgery patients without new-onset AD
Number of subjects: 10
Study 18509559 — intervention group
Group type: EXPERIMENTAL
Intervention: Single home visit by an occupational therapist
Number of subjects: 95
Study 18509559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no home visit)
Number of subjects: 95
Study 18509559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 95
Study 16579718 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-focus group (viewing themselves on a TV monitor)
Number of subjects: 51
Study 16579718 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (instructed to focus on their thoughts, body sensations, mood, and performance)
Number of subjects: 51
Study 16579718 — intervention group
Group type: COMPARATOR
Intervention: No instruction group
Number of subjects: 51
Study 12971703 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine (10 mg every fourth day, totalling 100 mg in 36 days)
Number of subjects: 24
Study 12971703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10702432 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified left double-lumen tube (L-DLT)
Number of subjects: 40
Study 10702432 — intervention group
Group type: COMPARATOR
Intervention: Right double-lumen tube (R-DLT)
Number of subjects: 40
Study 9088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype DPI (2 x 100 micrograms salbutamol)
Number of subjects: 10
Study 9088593 — intervention group
Group type: COMPARATOR
Intervention: MDI (Ventolin, 2 x 100 micrograms salbutamol)
Number of subjects: 10
Study 9088593 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype DPI
Number of subjects: 10
Study 9088593 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 10
Study 7880370 — intervention group
Group type: EXPERIMENTAL
Intervention: Karaya-based barrier
Number of subjects: 112
Study 7880370 — intervention group
Group type: COMPARATOR
Intervention: Pectin-based barrier
Number of subjects: 112
Study 7880370 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of tape used
Number of subjects: 112
Study 3066240 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (PF)
Number of subjects: 40
Study 3066240 — intervention group
Group type: COMPARATOR
Intervention: Propanidid (PD)
Number of subjects: 40
Study 29266773 — intervention group
Group type: EXPERIMENTAL
Intervention: Myb28B/B broccoli soup
Number of subjects: 10
Study 29266773 — intervention group
Group type: EXPERIMENTAL
Intervention: Myb28B/V broccoli soup
Number of subjects: 10
Study 29266773 — intervention group
Group type: EXPERIMENTAL
Intervention: Myb28V/V broccoli soup
Number of subjects: 10
Study 29266773 — intervention group
Group type: COMPARATOR
Intervention: All broccoli genotypes
Number of subjects: 10
Study 28778219 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches starting at 5 μg/h, titrated to a maximum of 40 μg/h over 6 weeks, continued for 11 weeks.
Number of subjects: 114
Study 28778219 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine (TDB) patches
Number of subjects: 114
Study 26684994 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Visualization (IV) eyewear during oral debridement (Group A)
Number of subjects: 30
Study 26684994 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Visualization (IV) eyewear during oral debridement (Group B)
Number of subjects: 30
Study 26684994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined mean calmness scores for both groups
Number of subjects: 30
Study 26684994 — intervention group
Group type: COMPARATOR
Intervention: Baseline DAS‐R anxiety levels for Group A
Number of subjects: 30
Study 26684994 — intervention group
Group type: COMPARATOR
Intervention: Baseline DAS‐R anxiety levels for Group B
Number of subjects: 30
Study 24107473 — intervention group
Group type: EXPERIMENTAL
Intervention: PiP intervention (outdoor playground-based physical activity intervention)
Number of subjects: 150
Study 24107473 — intervention group
Group type: COMPARATOR
Intervention: Control arm (usual practice)
Number of subjects: 150
Study 21236234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium breve BBG-01
Number of subjects: 0
Study 21236234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with PELF (cisplatin 40 mg/m² on days 1 and 5, epirubicin 30 mg/m² on days 1 and 5, L-leucovorin 100 mg/m² on days 1-4, and 5-fluorouracil 300 mg/m² on days 1-4)
Number of subjects: 258
Study 18334706 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 258
Study 17190893 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d
Number of subjects: 1099
Study 17190893 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 1099
Study 17190893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study 17190893 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (both doses)
Number of subjects: 1099
Study 17190893 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 1099
Study 14610129 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic CH patients
Number of subjects: 10
Study 14610129 — intervention group
Group type: EXPERIMENTAL
Intervention: CH patients in remission
Number of subjects: 10
Study 14610129 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 10
Study 10731626 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg iv)
Number of subjects: 16
Study 10731626 — intervention group
Group type: COMPARATOR
Intervention: MDMA (1.5 mg/kg po)
Number of subjects: 16
Study 9363712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical insemination by straw
Number of subjects: 91
Study 9363712 — intervention group
Group type: COMPARATOR
Intervention: Cervical cap with intracervical reservoir
Number of subjects: 91
Study 9363712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cap
Number of subjects: 91
Study 1543796 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40
Study 1543796 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 40
Study 1543796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3085428 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam orally
Number of subjects: 100
Study 3085428 — intervention group
Group type: COMPARATOR
Intervention: 10 mg diazepam as a rectal solution
Number of subjects: 100
Study 29475121 — intervention group
Group type: EXPERIMENTAL
Intervention: True indoor air filtration
Number of subjects: 70
Study 27891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk
Number of subjects: 696
Study 27891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle risk
Number of subjects: 696
Study 27891830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined genetic/lifestyle risks
Number of subjects: 696
Study 27891830 — intervention group
Group type: COMPARATOR
Intervention: No risk information (control)
Number of subjects: 696
Study 23313811 — intervention group
Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (600 mg weekly)
Number of subjects: 227
Study 23313811 — intervention group
Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (1200 mg EOW)
Number of subjects: 227
Study 23313811 — intervention group
Group type: EXPERIMENTAL
Intervention: epratuzumab 2400 mg cumulative dose (all patients)
Number of subjects: 227
Study 23313811 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 227
Study 24362859 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led smoking prevention intervention with extracurricular activities including the 'Smoking Prevention Tour' (4-hour activity) and 'Smoke-free Schools' intervention.
Number of subjects: 2476
Study 24362859 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 2476
Study 20024491 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo rFVIIa administration (45, 90, or 180 microg/kg)
Number of subjects: 30
Study 20024491 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo rFVIIa spiking (0.6, 1.2, or 2.4 microg/ml)
Number of subjects: 30
Study 20024491 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM and TEG analysis
Number of subjects: 30
Study 20024491 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo rFVIIa administration
Number of subjects: 30
Study 18786111 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI decrease by > or =70 points for the last two consecutive visits
Number of subjects: 0
Study 18786111 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI decrease in baseline by > or =100 points
Number of subjects: 0
Study 18786111 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI decrease by 50, 70, 100, or 150 points; decrease by 25% from baseline and by 70 or 100 points; CDAI <100 or 150 points; CDAI <150 points plus decrease by 70 or 100 points; CDAI <150 points at any time sustained for the duration of the trial; or decrease in the CDAI by 70 points for the last two consecutive visits
Number of subjects: 0
Study 15831652 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 1683
Study 15831652 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 1683
Study 12851352 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar fascia tissue-stretching program
Number of subjects: 101
Study 12851352 — intervention group
Group type: COMPARATOR
Intervention: Achilles tendon-stretching program
Number of subjects: 101
Study 10482309 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 10482309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8582958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU HCG subcutaneously (s.c.)
Number of subjects: 104
Study 8582958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG subcutaneously (s.c.)
Number of subjects: 104
Study 8582958 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU HCG intramuscularly (i.m.)
Number of subjects: 104
Study 8582958 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 IU HCG intramuscularly (i.m.)
Number of subjects: 104
Study 8582958 — intervention group
Group type: COMPARATOR
Intervention: 5000 IU HCG
Number of subjects: 104